Royalty Pharma (RPRX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
RPRXRoyalty Pharma(RPRX) Zacks Investment Research·2024-05-10 01:01

For the quarter ended March 2024, Royalty Pharma (RPRX) reported revenue of 717million,down36.6717 million, down 36.6% over the same period last year. EPS came in at 0.98, compared to 1.60intheyear−agoquarter.ThereportedrevenuecomparestotheZacksConsensusEstimateof1.60 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of 671.45 million, representing a surprise of +6.79%. The company delivered an EPS surprise of +2.08%, with the consensus EPS estimate being $0.96. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall S ...